Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1946-1955, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kárpáti, L.
Right arrow Articles by Muszbek, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kárpáti, L.
Right arrow Articles by Muszbek, L.
Related Collections
Right arrow Hemostasis and Thrombosis
Right arrow Proteomics and Protein Markers
Right arrow Hematology
(Clinical Chemistry. 2000;46:1946-1955.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

A Modified, Optimized Kinetic Photometric Assay for the Determination of Blood Coagulation Factor XIII Activity in Plasma

Levente Kárpáti1, Botond Penke3, Éva Katona1, István Balogh1, György Vámosi2 and László Muszbek1,a

1 Department of Clinical Biochemistry and Molecular Pathology, and
2 Cell Biophysics Research Group of the Hungarian Academy of Sciences, Medical and Health Science Center, University of Debrecen, Debrecen H-4012, Hungary.

3 Department of Medical Chemistry, Medical Center, University of Szeged, Szeged H-6720, Hungary.
a Address correspondence to this author at: Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Science Center, University of Debrecen, PO Box 40, Debrecen H-4012, Hungary. Fax 36-52-417-631; e-mail muszbek{at}jaguar.dote.hu

Background: Blood coagulation factor XIII (FXIII) is a zymogen that is transformed into an active transglutaminase by thrombin and Ca2+. FXIII plays an essential role in fibrin stabilization and in the protection of fibrin from proteolytic degradation. No convenient method has been available for the measurement of FXIII activity in plasma. The aim of the present study was to improve and optimize a kinetic photometric FXIII assay originally developed in our laboratory.

Methods: In the assay, FXIII was activated by thrombin and Ca2+. Fibrin polymerization was prevented by an inhibitory tetrapeptide. Glycine-ethyl ester and a glutamine residue of a synthetic dodecapeptide served as acyl acceptor and acyl donor transglutaminase substrates, respectively. The amount of ammonia released during the reaction was monitored using glutamate dehydrogenase and NADPH.

Results: The use of a new glutamine substrate and optimization of activator and substrate concentrations increased sensitivity. Substitution of NADPH for NADH and introduction of an appropriate blank eliminated systemic overestimation of FXIII activity. The recovery of FXIII was 96%, the assay was linear up to 470 U/L, the detection limit was 1 U/L, and the imprecision (CV) was <8% even at very low FXIII activities. A reference interval of 108–224 U/L (69–143%) was established. The results correlated well with results obtained by an immunoassay specific for plasma FXIII.

Conclusions: The optimized FXIII assay is a simple, rapid method for the diagnosis of inherited or acquired FXIII deficiencies and increased FXIII concentrations. It can be easily adapted to clinical chemistry analyzers.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Pharmacol. Exp. Ther.Home page
N. D. Papamichael, E. M. Stathopoulou, V. D. Roussa, L. D. Tsironis, A. P. Kotsia, R.-M. Stanica, V. Moussis, V. Tsikaris, C. S. Katsouras, A. D. Tselepis, et al.
Effect of a Synthetic Peptide Corresponding to Residues 313 to 320 of the {alpha}IIb Subunit of the Human Platelet Integrin {alpha}IIb{beta}3 on Carotid Artery Thrombosis in Rabbits
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 634 - 640.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Ajzner, A. Schlammadinger, A. Kerenyi, Z. Bereczky, E. Katona, G. Haramura, Z. Boda, and L. Muszbek
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency
Blood, January 15, 2009; 113(3): 723 - 725.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. H. Shemirani, E. Szomjak, Z. Csiki, E. Katona, Z. Bereczky, and L. Muszbek
Elevated factor XIII level and the risk of peripheral artery disease
Haematologica, September 1, 2008; 93(9): 1430 - 1432.
[Full Text] [PDF]

Home page
 haematolHome page
Z. Bereczky, E. Balogh, E. Katona, I. Czuriga, I. Edes, and L. Muszbek
Elevated factor XIII level and the risk of myocardial infarction in women
Haematologica, February 1, 2007; 92(2): 287 - 288.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
Y.-W. Wu and Y.-H. Tsai
A Rapid Transglutaminase Assay for High-Throughput Screening Applications
J Biomol Screen, October 1, 2006; 11(7): 836 - 843.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
R. Ponce, K. Armstrong, K. Andrews, J. Hensler, K. Waggie, J. Heffernan, T. Reynolds, and M. Rogge
Safety of Recombinant Human Factor XIII in a Cynomolgus Monkey Model of Extracorporeal Blood Circulation
Toxicol Pathol, October 1, 2005; 33(6): 702 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Mazooz, T. Mehlman, T.-S. Lai, C. S. Greenberg, M. W. Dewhirst, and M. Neeman
Development of Magnetic Resonance Imaging Contrast Material for In vivo Mapping of Tissue Transglutaminase Activity
Cancer Res., February 15, 2005; 65(4): 1369 - 1375.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.